logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Approves Pfizer's Bosulif For Patients With Previously Treated Ph+ CML

Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration or FDA has approved Bosulif (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia or CML with resistance, or intolerance to prior therapy.

The company said Patients in the registrational trial included patients who were previously treated with imatinib [Gleevec] or imatinib plus at least one second generation tyrosine kinase inhibitor or TKI. Once daily Bosulif represents the only therapy approved with pivotal trial data that included CML patients treated with imatinib followed by a second generation TKI.

Bosulif is a kinase inhibitor that limits cancer cell growth by inhibiting the Abl and Src signaling pathways. The recommended dose of Bosulif is 500 mg, orally, taken once daily, with food.

The company said that the most common adverse reactions observed in greater than 20 percent of the patients in the Phase 1/2 safety population (n=546) were diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia and fatigue.

Pfizer said that BOSULIF may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised of potential hazard to the fetus and to avoid becoming pregnant while receiving Bosulif.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
IKEA is voluntarily recalling 29 million chests and dressers in the U.S. following reports of several injuries, including deaths of three children caused by them tipping over. The recalled chests and dressers are unstable if they are not properly anchored to the wall, posing a serious tip-over and... Dow Chemical Co. (DOW) Tuesday announced its plans to eliminate about 2,500 jobs, or about 4 percent of global workforce, as the company takes full control of Dow Corning Corp., the joint venture formed in 1943 with Corning Inc. Dow Chemicals now owns Dow Corning Corp. completely after Corning exchanged... Quote-to-Cash software provider Apttus is planning Initial Public Offering in the first half of 2017, reported MarketWach.
comments powered by Disqus
Follow RTT